Table 2.
Clinical and serological features of patients treated with anakinra.
| Anakinra (n=52) | Standard of care(n=88) | p value | PaO2/FiO2 ratio ≥ 100 mmHg | PaO2/FiO2 ratio < 100 mmHg | |||||
|---|---|---|---|---|---|---|---|---|---|
| Anakinra(n=16) | Standard of care(n=43) | p value | Anakinra(n=36) | Standard of care(n=45) | p value | ||||
| Age (years) | 63 (55-74) | 62 (57-73) | 60 (51-71) | 61 (55-72) | 0.77 | 64 (56-74) | 63 (58-73) | 0.9 | |
| Male sex, n (%) | 33 (63%) | 50 (57%) | 0.59 | 13 (81%) | 31 (72%) | 0.74 | 20 (56%) | 19 (42%) | 0.27 |
| Comorbidities | |||||||||
| HBP | 22 (42%) | 39 (44%) | 0.86 | 4 (25%) | 17 (40%) | 0.37 | 18 (50%) | 22 (49%) | 0.99 |
| CAD | 6 (11%) | 16 (18%) | 0.34 | 0 (0%) | 8 (19%) | 0.09 | 6 (16%) | 8 (18%) | 0.99 |
| Type 2 diabetes | 12 (23%) | 18 (21%) | 0.83 | 1 (6%) | 8 (19%) | 0.42 | 11 (30%) | 10 (22%) | 0.45 |
| COPD | 3 (6%) | 7 (8%) | 0.74 | 0 (0%) | 3 (7%) | 0.56 | 3 (8%) | 4 (9%) | 0.99 |
| Cancer | 2 (4%) | 8 (9%) | 0.32 | 1 (6%) | 7 (16%) | 0.43 | 1 (3%) | 1 (2%) | 0.99 |
| CRF | 4 (8%) | 4 (5%) | 0.47 | 0 (0%) | 1 (2%) | 0.99 | 4 (11%) | 3 (7%) | 0.69 |
| PaO2/FiO2 ratio (mmHg) | 81 (70-113) | 96 (72-143) | 0.09 | 143 (117-181) | 143 (122-189) | 0.84 | 77 (67-85) | 73 (61-86) | 0.74 |
| Laboratory values | |||||||||
| LAD (125-220 IU/L) |
458 (372-580) | 510 (393-630) | 0.21 | 392 (286-551) | 428 (383-542) | 0.25 | 499 (389-591) | 565 (436-726) | 0.08 |
| CRP (< 6 mg/L) | 157 (120-224) | 171 (122-232) | 0.36 | 130 (102-162) | 153 (119-199) | 0.12 | 165 (128-240) | 202 (135-238. | 0.65 |
| Ferritin (30-400 ng/mL) |
1547 (937-3521) | 2347 (1242-3549) | 0.17 | 1773 (912-3347) | 2486 (1291-3436) | 0.4 | 1462 (929-3847) | 1717 (1198-3871) | 0.33 |
| IL6 (<7 pg/mL) | 48 (27-99) | 65 (37-172) | 0.63 | 75 (69-82) | 47 (26-153) | 0.22 | 59 (42-831) | 105 (66-287) | 0.41 |
Results are reported as median (interquartile range) unless specified; statistically significant p value < 0.05. HBP, high blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; LAD, lactate dehydrogenase; CRP, C-reactive protein; IL-6, interleukin-6.